GemVax & Kael

Industry · 8 registered clinical trials.

Status	Trial	Phase	Started
Completed	Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects Neuro-Degenerative Disease	Phase 1	2024-10-08
Completed	Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL Progressive Supranuclear Palsy	Phase 2	2023-12-12
Completed	GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) Progressive Supranuclear Palsy	Phase 2	2023-06-14
Completed	GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) Mild to Moderate Alzheimer's Disease	Phase 2	2022-10-05
Completed	Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) Benign Prostatic Hyperplasia (BPH)	Phase 3	2019-10-30
Withdrawn	GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD) Moderate Alzheimer's Disease	Phase 2	2019-09-01
Completed	Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Alzheimer Disease	Phase 2	2017-09-05
Completed	A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH Benign Prostatic Hyperplasia (BPH)	Phase 2	2015-10-01